Aeglea BioTherapeutics In... (AGLE)
Company Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases.
The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.
It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria.
In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs.
The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.
Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
| Country | United States |
| IPO Date | Apr 7, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Jonathan D. Alspaugh |
Contact Details
Address: 805 Las Cimas Parkway Austin, Texas United States | |
| Website | https://www.aeglea.com |
Stock Details
| Ticker Symbol | AGLE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636282 |
| CUSIP Number | 00773J103 |
| ISIN Number | US00773J2024 |
| Employer ID | 46-4312787 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey M. Goldberg | Pres, Chief Executive Officer & Director |
| Dr. Cameron Turtle DPHIL, Ph.D. | Chief Operating Officer & Principal Executive Officer |
| Dr. Leslie S. Sloan Ph.D. | Chief Operating Officer |
| Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary |
| Scott L. Burrows | Chief Financial Officer |
| Cortney Caudill M.B.A. | Chief Product Officer |
| Dr. F. Andrew Dorr | Executive Officer |
| Dr. Josie Gayton Ph.D. | Senior Vice President of Program Strategy, Operations & Chief of Staff |
| Dr. Kelly Boothe Ph.D. | Senior Director of Corporate Communications & Investor Relations |
| Dr. Linda Neuman M.D., MBA | Chief Medical Officer |
| Dr. Scott W. Rowlinson | Vice President of Research |
| Joey Perrone | Vice President of Finance & Investor Relations |
| Michael C. Hanley M.B.A. | Chief Commercial Officer & Chief Bus. Officer |
| Tricia Sterling | Vice President of Patient Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 05, 2025 | S-8 | Filing |
| Aug 05, 2025 | 8-K | Current Report |
| Aug 05, 2025 | 10-Q | Quarterly Report |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jul 16, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |
| Jun 02, 2025 | 4 | Filing |